Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127161271 | 12716127 | 1 | I | 20100607 | 20160825 | 20160906 | 20160906 | EXP | GB-PERRIGO-16GB019534 | PERRIGO | 0.00 | Y | 0.00000 | 20160906 | CN | US | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127161271 | 12716127 | 1 | PS | RANITIDINE HYDROCHLORIDE. | RANITIDINE HYDROCHLORIDE | 1 | Unknown | 150 MG, BID | Y | U | UNKNOWN | 76195 | 150 | MG | TABLET | ||||
| 127161271 | 12716127 | 2 | SS | ATORVASTATIN | ATORVASTATIN | 1 | Unknown | 20 MG, UNKNOWN | Y | U | UNKNOWN | 0 | 20 | MG | |||||
| 127161271 | 12716127 | 3 | SS | EZETIMIBE. | EZETIMIBE | 1 | Oral | 10 MG, UNK | Y | U | UNKNOWN | 0 | 10 | MG | |||||
| 127161271 | 12716127 | 4 | SS | INDAPAMIDE. | INDAPAMIDE | 1 | Unknown | 3 MG, UNKNOWN | Y | U | UNKNOWN | 0 | 3 | MG | |||||
| 127161271 | 12716127 | 5 | SS | PERINDOPRIL | PERINDOPRIL | 1 | Unknown | 4 MG, UNKNOWN | Y | U | UNKNOWN | 0 | 4 | MG | |||||
| 127161271 | 12716127 | 6 | C | GLICLAZIDE | GLICLAZIDE | 1 | Unknown | UNK | U | U | UNKNOWN | 0 | |||||||
| 127161271 | 12716127 | 7 | C | ASPIRIN /00002701/ | ASPIRIN | 1 | Oral | 75 MG, UNK | U | U | UNKNOWN | 0 | 75 | MG | |||||
| 127161271 | 12716127 | 8 | C | ASPIRIN /00002701/ | ASPIRIN | 1 | Oral | 75 MG, UNK | U | U | 0 | 75 | MG | ||||||
| 127161271 | 12716127 | 9 | C | GLUCOSAMINE | GLUCOSAMINE | 1 | Oral | 100 MG, UNK | U | U | UNKNOWN | 0 | 100 | MG | |||||
| 127161271 | 12716127 | 10 | C | GLUCOSAMINE | GLUCOSAMINE | 1 | Oral | 100 MG, UNK | U | U | 0 | 100 | MG | ||||||
| 127161271 | 12716127 | 11 | C | NITROGLYCERIN. | NITROGLYCERIN | 1 | Sublingual | 2 DF, UNK | U | U | UNKNOWN | 0 | 2 | DF | |||||
| 127161271 | 12716127 | 12 | C | NITROGLYCERIN. | NITROGLYCERIN | 1 | Sublingual | 2 DF, UNK | U | U | 0 | 2 | DF | ||||||
| 127161271 | 12716127 | 13 | C | TROLNITRATE PHOSPHATE | 2 | Unknown | UNK | U | U | UNKNOWN | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127161271 | 12716127 | 1 | Cerebrovascular accident prophylaxis |
| 127161271 | 12716127 | 2 | Cerebrovascular accident prophylaxis |
| 127161271 | 12716127 | 3 | Product used for unknown indication |
| 127161271 | 12716127 | 4 | Cerebrovascular accident prophylaxis |
| 127161271 | 12716127 | 5 | Cerebrovascular accident prophylaxis |
| 127161271 | 12716127 | 6 | Product used for unknown indication |
| 127161271 | 12716127 | 7 | Product used for unknown indication |
| 127161271 | 12716127 | 9 | Product used for unknown indication |
| 127161271 | 12716127 | 11 | Product used for unknown indication |
| 127161271 | 12716127 | 13 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127161271 | 12716127 | HO |
| 127161271 | 12716127 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127161271 | 12716127 | Drug interaction | |
| 127161271 | 12716127 | Hypotension | |
| 127161271 | 12716127 | Stevens-Johnson syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127161271 | 12716127 | 1 | 2010 | 0 | ||
| 127161271 | 12716127 | 2 | 2010 | 0 | ||
| 127161271 | 12716127 | 3 | 2010 | 0 | ||
| 127161271 | 12716127 | 4 | 2010 | 0 | ||
| 127161271 | 12716127 | 5 | 2010 | 0 |